Adenocarcinoma of Lung: all 315 studies

Page 3 of 4. Open to participants first (83), then studies with results posted, then the rest; newest registration first within each.

• Bevacizumab After Chemoradiotherapy For Locally Advanced Lung AdenocarcinomaCompletedNCT03904563Phase 2
• The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)Status unknownNCT03896958
• A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung AdenocarcinomaTerminatedNCT03891173Phase 2
• The Tracking Molecular Evolution for NSCLC (T-MENC) StudyStatus unknownNCT03838588
• Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung AdenocarcinomaStatus unknownNCT03728374Phase 2
• Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung AdenocarcinomaStatus unknownNCT03709147Phase 2
• Outcomes Following Omission of Daily Routine Chest Radiographs Following Pulmonary ResectionCompletedNCT03704870Phase 2
• Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC AdenocarcinomaTerminatedNCT03696212Phase 1/2
• Investigation of the Contents and Prognostic Values of Glucose Metabolism Molecules in Patients With Lung AdenocarcinomaStatus unknownNCT03641105
• EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual ProgressionCompletedNCT03544814Phase 2
• Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR MutationStatus unknownNCT03486496Phase 2
• Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced NSCLCStatus unknownNCT03402464Phase 2
• Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung CancerActive, not recruitingNCT03391869Phase 3
• Study of Apatinib as the Maintenance Therapy in Advanced Lung AdenocarcinomaStatus unknownNCT03376737Phase 2
• Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC AdenocarcinomaWithdrawnNCT03361319Phase 1/2
• Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)CompletedNCT03345810Phase 2
• Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cmStatus unknownNCT03254004Phase 2
• Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung CancerActive, not recruitingNCT03110978Phase 2
• Circulating Tumor DNA (ctDNA) as a Prognostic Tool in Patients With Advanced Lung AdenocarcinomaStatus unknownNCT03090815
• Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in ChinaCompletedNCT03059641
• Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLCCompletedNCT03044626Phase 2
• Detection of CSF Next Generation Sequencing in the Application of Brain Metastases From Lung Adenocarcinoma or Meningeal MetastasisStatus unknownNCT03029065
• Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma (ECTOP-1002)CompletedNCT02980991Phase 2
• Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)CompletedNCT02979821Phase 2
• EGFRdelEx19 and KRAS Exon 2 Mutation Detection in EBUS-TBNACompletedNCT02975752
• A Phase Ib Study of LXH254-centric Combinations in NSCLC or MelanomaTerminatedNCT02974725Phase 1
• Low-dose Protocol for Computed Tomography-guided Lung BiopsyCompletedNCT02971176Not applicable
• Application of Detecting Circulating Tumor Cells in the Accurate Treatment of Early Stage Lung AdenocarcinomaStatus unknownNCT02951897Not applicable
• Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled TrialStatus unknownNCT02951637Phase 2
• A+C in Metastatic Lung Adenocarcinoma CancerStatus unknownNCT02946359Phase 2
• ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLCStatus unknownNCT02946216
• Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary AdenocarcinomaStatus unknownNCT02929693Phase 3
• Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung AdenocarcinomaStatus unknownNCT02898857
• Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas)TerminatedNCT02893332Phase 3
• Retrospective Analysis of the Expression of the Neurotensin Receptor by Metastatic Lung AdenocarcinomasWithdrawnNCT02891733
• Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary AdenocarcinomaCompletedNCT02889692Phase 3
• Molecular Analysis of 150 Lung AdenocarcinomaStatus unknownNCT02843711
• Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung AdenocarcinomaStatus unknownNCT02804646Phase 4
• A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI TherapyStatus unknownNCT02788058Phase 2
• Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI TherapyStatus unknownNCT02787447Phase 2
• A Study to Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation TestStatus unknownNCT02738684
• Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR MutationStatus unknownNCT02737774Phase 2
• Circulating Tumor DNA in Patients at High Risk for Lung CancerTerminatedNCT02715102
• Tarceva With or Without Apatinib in the Advanced Lung AdenocarcinomaStatus unknownNCT02704767Phase 2
• Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFRStatus unknownNCT02691871Phase 1
• Vitamin Supplementation in NSCLC Patients on Pemetrexed Based ChemotherapyCompletedNCT02679443Not applicable
• Intraoperative Imaging of Pulmonary AdenocarcinomaWithdrawnNCT02653612Phase 1
• Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung AdenocarcinomaTerminatedNCT02621333Phase 2
• An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase InhibitorsCompletedNCT02616211
• Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung CancerCompletedNCT02535325Phase 1
• Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung AdenocarcinomaStatus unknownNCT02518802Phase 3
• The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFRActive, not recruitingNCT02493582Phase 2
• Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the LungWithdrawnNCT02466568Phase 1/2
• Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung AdenocarcinomaStatus unknownNCT02399566Phase 4
• HS-PCI in Locally Advanced Adenocarcinoma of the LungWithdrawnNCT02341170Not applicable
• Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung CancerStatus unknownNCT02288026
• High-dose Pemetrexed to Treat Lung Adenocarcinoma With Brain MetastasesStatus unknownNCT02284490Phase 2
• Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene MutationStatus unknownNCT02283424Phase 4
• Blood Detection of EGFR Mutation For Iressa TreatmentStatus unknownNCT02282267Not applicable
• Telomere Biology in Early Adenocarcinoma of the LungStatus unknownNCT02239432
• Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain MetastasesTerminatedNCT02162537Phase 3
• A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung AdenocarcinomaStatus unknownNCT02146118Phase 2
• Comparative Study of Chemoradiation and Sequential Chemoradiation About Lung Adenocarcinoma Patients With Postoperative in pN2Status unknownNCT02132143Not applicable
• Whole-Exome Sequencing (WES) of Cancer PatientsCompletedNCT02127359
• Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-upTerminatedNCT02121925
• Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung AdenocarcinomasCompletedNCT02120807Phase 1
• Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung AdenocarcinomaStatus unknownNCT02103257Phase 4
• A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung AdenocarcinomaCompletedNCT02093000
• Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLCWithdrawnNCT02059967Phase 1
• Comparison of cVATS Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With MicroinvasionStatus unknownNCT02011997Phase 3
• Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung CancerCompletedNCT01958372Phase 1
• Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and PancreasStatus unknownNCT01942629
• Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung AdenocarcinomaCompletedNCT01851096Phase 1
• NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung AdenocarcinomaTerminatedNCT01819428Phase 2
• Molecular Epidemiology of Lung Adenocarcinoma in Multi-ethnic Asian PhenotypeStatus unknownNCT01774526Not applicable
• Efficacy Study of Chinese Medicine Plus EGFR-TKI Versus EGFR-TKI in Advanced Pulmonary AdenocarcinomaStatus unknownNCT01745302
• Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor CareCompletedNCT01726296Not applicable
• Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma PatientsCompletedNCT01719536Phase 3
• Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung CancerTerminatedNCT01707823Early Phase 1
• Photodynamic Therapy in Treating Patients With Lung CancerCompletedNCT01668823Phase 1
• Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung AdenocarcinomaStatus unknownNCT01665417Phase 4
• Prophylactic Cranial Irradiation in Patients With Lung Adenocarcinoma With High Risk of Brain MetastasisCompletedNCT01603849Not applicable
• Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab in Unresectable, Locally Advanced Lung AdenocarcinomaCompletedNCT01588704Phase 2
• Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain MetastasesCompletedNCT01578668Phase 2
• The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With EndostarStatus unknownNCT01564329Phase 2
• Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the LungCompletedNCT01561456Phase 2
• Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never SmokersStatus unknownNCT01502202Phase 2
• Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment StrategyStatus unknownNCT01482585
• Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain MetastasisTerminatedNCT01363557Not applicable
• Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By SurgeryActive, not recruitingNCT01345851Not applicable
• Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung AdenocarcinomaStatus unknownNCT01249066
• Expression of Optic Atrophy Type 1 (OPA1) Protein in Lung AdenocarcinomaStatus unknownNCT01249053
• A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR MutationsStatus unknownNCT01131429Phase 2
• A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung AdenocarcinomaCompletedNCT01051934Phase 1
• Lung Cancer Mutation Consortium ProtocolCompletedNCT01014286
• Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus CisplatinCompletedNCT00966914Phase 3
• Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung AdenocarcinomaStatus unknownNCT00903292Not applicable
• Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)CompletedNCT00511485Phase 2
• Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung CancerActive, not recruitingNCT00499330
• Sorafenib in BAC or Never-Smokers With Lung AdenocarcinomaCompletedNCT00456716Phase 2

← Adenocarcinoma of Lung overview